文献速递心脑血管急症重症综合管理与镇静镇痛

动脉瘤性或中脑周围蛛网膜下腔出血患者口服或持续动脉内尼莫地平后动脉性低血压发生率

Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage.
PubMed 文献 · Neurocrit Care · 2019-01-01
一句话结论高级别蛛网膜下腔出血患者口服尼莫地平常需减量或停药,口服溶液比片剂更易致血压下降,动脉内输注<1 mg/h时血浆浓度与口服60 mg每4小时相当。

该前瞻性研究纳入38例动脉瘤性或中脑周围蛛网膜下腔出血的ICU患者,观察动脉血压和尼莫地平剂量,并用液相色谱-串联质谱法测血浆浓度。目标全剂量口服尼莫地平60 mg每4小时仅在57.2%的观察日能给予;治疗前14天内观察到97次可能由尼莫地平引起的相关动脉性低血压。口服溶液给药后血压下降次数约为片剂的3倍,但两种剂型的血浆水平无差异。高级别SAH患者低血压及减量或停药更频繁;持续动脉内输注尼莫地平(CIAN)期间血浆浓度未超过口服给药。

要点

  • 目标口服尼莫地平60 mg每4小时仅在57.2%的观察日能给予全剂量。
  • 治疗前14天内观察到97次可能由尼莫地平引起的相关动脉性低血压。
  • 口服溶液给药后血压下降次数约为片剂的3倍,但两种剂型血浆水平无差异。
  • 高级别SAH患者动脉性低血压及减量或停药比低级别SAH更频繁。
  • 持续动脉内尼莫地平输注速率<1 mg/h时,静脉血浆浓度与口服60 mg每4小时相似。

适用人群与场景

  • 动脉瘤性或中脑周围蛛网膜下腔出血、在重症监护室接受治疗的患者。
  • 发生严重难治性脑血管痉挛时可能需要持续动脉内输注尼莫地平以避免脑缺血。

处置流程与药物剂量

  • 口服尼莫地平目标全剂量为60 mg每4小时。
  • 出现尼莫地平相关动脉性低血压时需减量或停药。
  • 持续动脉内输注尼莫地平速率<1 mg/h时,静脉血浆浓度与口服60 mg每4小时相似。

红旗征与不能漏的情况

  • 尼莫地平给药后出现动脉性低血压,需减量或停药。

研究设计与关键结果

  • 前瞻性研究,观察期1年,纳入38例动脉瘤性或中脑周围蛛网膜下腔出血的ICU患者,收集动脉血压和尼莫地平剂量数据,并用液相色谱-串联质谱法测血浆浓度。
  • 目标口服尼莫地平60 mg每4小时仅在57.2%的观察日能给予全剂量。
  • 治疗前14天内观察到97次可能由尼莫地平引起的相关动脉性低血压。
  • 口服溶液给药后血压下降次数约为片剂的3倍,但两种剂型尼莫地平血浆水平无差异。
  • 高级别SAH患者动脉性低血压及减量或停药比低级别SAH更频繁。
  • 持续动脉内输注尼莫地平期间血浆浓度未超过口服给药;输注速率<1 mg/h时静脉血浆浓度与口服60 mg每4小时相似。

证据类型、等级与局限

  • 证据类型:前瞻性观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 高级别SAH患者口服尼莫地平常需减量或停药,应监测动脉血压。
  • 口服尼莫地平溶液比片剂更易引起血压下降,选择剂型时需考虑此差异。
  • 持续动脉内输注尼莫地平速率<1 mg/h时,血浆浓度与口服60 mg每4小时相似,可据此理解动脉内给药的全身暴露水平。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Oral nimodipine is used for prophylaxis and treatment of delayed cerebral ischemia in patients with aneurysmal or perimesencephalic subarachnoid hemorrhage (SAH). In cases of serious refractory cerebral vasospasm, a continuous intra-arterial (IA) infusion of nimodipine (CIAN) may be required to avoid cerebral ischemia. Nimodipine can cause arterial hypotension requiring either a dosage reduction or its discontinuation. Aim of the present study was to examine the effect of different nimodipine formulations on arterial blood pressure in aneurysmal or perimesencephalic SAH patients and to measure the plasma levels after both, peroral administration as tablet or solution and IA infusion.

METHODS: In a prospective setting, over a 1-year observation period, data on the course of arterial blood pressure and nimodipine dosage were collected for 38 patients undergoing treatment for aneurysmal or perimesencephalic SAH in an intensive care unit. In addition, plasma concentrations of nimodipine were measured by liquid chromatography-tandem mass spectrometry.

RESULTS: The intended full dose of 60 mg of nimodipine given orally every 4 h could only be administered on 57.2% of the examined days. Ninety-seven episodes of relevant arterial hypotension probably caused by the administration of nimodipine were observed within the first 14 days of treatment. Drops in blood pressure occurred about three times as often after administration of nimodipine as oral solution than as tablet. However, there were no differences in nimodipine plasma levels between the two formulations. In patients suffering from higher-grade SAH, arterial hypotension and consequent dosage reduction or discontinuation of nimodipine were more frequent than in patients with lower-grade SAH. Plasma concentrations of nimodipine during CIAN did not exceed those achieved by oral administration.

CONCLUSIONS: Dosage reduction or discontinuation of oral nimodipine is often necessary in patients with higher-grade SAH. Oral nimodipine solutions cause drops in blood pressure more frequently than tablets. Intra-arterial infusion rates of less than 1 mg/h result in venous plasma concentrations of nimodipine similar to those observed after oral application of 60 mg every 4 h.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Kieninger M, Gruber M, Knott I, et al. Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage. Neurocrit Care. 2019. PMID: 30725331. doi:10.1007/s12028-019-00676-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。